Chugai Pharmaceutical Co., Ltd. (CHGCF)
OTC PINK OTC PINK Primary Summary
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2025 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q2 2025 Earnings Conference Call July 24, 2025 4:00 AM ET Company Participants a - Corporate Participant Iwaaki Taniguchi - Executive VP, Head of Finance Supervisory Division, CFO & Director Kae Miyata - Head of Corporate Communications Department Osamu Okuda - President, CEO & Chairman Tsukasa Kusano - Executive VP and Head of Project & Lifecycle Management Unit Conference Call Participants Akinori Ueda - Goldman Sachs Group, Inc., Research Division Fumiyoshi Sakai - UBS Investment Bank, Research Division Hidemaru Yamaguchi - Citigroup Inc., Research Division Kazuaki Hashiguchi - Daiwa Securities Co. Ltd.
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q4 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q4 2024 Earnings Conference Call January 30, 2025 3:30 AM ET Company Participants Kae Miyata - Head of Corporate Communications Department Osamu Okuda - Representative Director, President, and Chief Executive Officer Michiaki Tanaka - Head, R&D Portfolio Management Department, Project and Lifecycle Management Unit Iwaaki Taniguchi - Director, Executive Vice President, and Chief Financial Officer Takao Suzuki - Associate Vice President, Head of the Digital Transformation Unit Conference Call Participants Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - UBS Securities Seiji Wakao - JPMorgan Securities Hidemaru Yamaguchi - Citigroup Global Markets Stephen Barker - Jefferies Tony Ren - Macquarie Capital Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Miki Sogi - AllianceBernstein Japan Kae Miyata Ladies and gentlemen, thank you for attending the conference on FY 2024 December financial results for Chugai Pharmaceutical.
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q3 2024 Earnings Conference Call October 25, 2024 5:00 AM ET Company Participants Kae Miyata - Corporate Communications Department Osamu Okuda - President and CEO Tsukasa Kusano - Executive Vice President, Head, Project and Lifecycle Management Unit Iwaaki Taniguchi - Chief Financial Officer Junichi Takano - Head, Marketing and Sales Division Conference Call Participants Seiji Wakao - JPMorgan Hidemaru Yamaguchi - Citigroup Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Tony Ren - Macquarie Capital Hiroshi Wada - SMBC Nikko Securities Kazuaki Hashiguchi - Daiwa Securities Kasumi Haruta - UBS Securities Kae Miyata Thank you for joining Chugai Pharmaceutical's Earnings Call on the Financial Results for the Fiscal Year 2024 Third Quarter.
Chugai Pharmaceutical Co., Ltd. (CHGCF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Chugai Pharmaceutical Co., Ltd. ever had a stock split?
Chugai Pharmaceutical Co., Ltd. Profile
| Pharmaceuticals Industry | Healthcare Sector | Dr. Osamu Okuda CEO | OTC PINK Exchange | JP3519400000 ISIN |
| JP Country | 5,026 Employees | 31 Dec 2025 Last Dividend | 29 Jun 2020 Last Split | - IPO Date |
Overview
Chugai Pharmaceutical Co., Ltd. is a prominent entity in the pharmaceutical industry, boasting a comprehensive footprint in both the domestic Japanese market and various international territories. Founded in 1925, Chugai has established a formidable presence through its exhaustive endeavors in research, development, manufacture, sales, as well as the importation and exportation of pharmaceutical products. The company operates as a pivotal subsidiary of Roche Holding Ltd., showcasing a robust partnership that underlines its strategic alliances and collaborations. Chugai's legacy is built on its continuous innovation and commitment to addressing complex healthcare challenges, part of which is evidenced by its extensive product portfolio that spans across several therapeutic areas such as oncology, immunology, neuroscience, hematology, ophthalmology, and more.
Products and Services
- Oncology: Chugai Pharmaceutical's oncology segment is a cornerstone of its product line, featuring prominent drugs such as Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva. Each of these products plays a crucial role in cancer therapy, representing the company's significant contributions to combating various forms of cancer.
- Edirol (Osteoporosis Agent): Tailored for the treatment of osteoporosis, Edirol underscores Chugai's focus on bone health by helping to prevent fractures in patients with this condition.
- Mircera (Erythropoiesis Agent): This therapeutic agent targets anemia associated with chronic kidney disease, facilitating improved management of erythropoiesis, the process of red blood cell production.
- Oxarol (Secondary Hyperparathyroidism): Oxarol is designed to treat secondary hyperparathyroidism, showcasing Chugai's commitment to addressing complex conditions associated with chronic renal failure.
- Other Diseases: Beyond the core areas, Chugai Pharmaceutical addresses a wide array of diseases with products like Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. These treatments span conditions from blood disorders to viral infections, exemplifying the company's diversified approach to healthcare.
Moreover, Chugai Pharmaceutical Co., Ltd. is actively engaged in the development of product candidates in various stages for diseases across oncology, immunology, neuroscience, hematology, ophthalmology, and other therapeutic areas. This dynamic pipeline underscores the company's relentless pursuit of innovation and its commitment to addressing unmet medical needs around the globe.
Contact Information
